Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MTOR | P42345 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27775594 | 0.86 | MTOR (0.46) | ALDH1A1MTORMEN1KMT2AHDAC1 | |
| SCHEMBL279656 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL18079795 | 0.81 | CES2 (0.54) | MTORHDAC1HDAC2GRM5TP53BP1 | |
| SCHEMBL18242327 | 0.81 | MTOR (0.44) | MTORHDAC1HDAC2GRM5TP53BP1 | |
| SCHEMBL3673834 | 0.81 | ATM (0.58) | ALDH1A1MTORHDAC1HDAC2GRM5 | |
| Ethane SCHEMBL7579504 | 0.80 | MTOR (0.55) | ALDH1A1MTORMEN1KMT2AHDAC1 | |
| SCHEMBL40282 | 0.79 | CA12 (0.58) | ALDH1A1MTORMEN1KMT2ATDP1 | |
| SCHEMBL29532021 | 0.79 | CA12 (0.58) | ALDH1A1MTORMEN1KMT2ATDP1 | |
| SCHEMBL2163420 | 0.79 | HDAC1 (0.45) | MTORHDAC1HDAC2GRM5TDP1 | |
| SCHEMBL7923301 | 0.78 | HDAC1 (0.49) | MTORMEN1KMT2AHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | claimed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | claimed |
| CN-106010316-A | Adhesive for steel volute and preparation method thereof | 保定亿嘉特种陶瓷制造有限公司 | 2016-10-12 | — | — | CN | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4648762-A2 | PPARG MODULATORS | University of Florida Research Foundation, Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12331240-B2 | Anthraquinone compound, liquid crystal composition containing said compound, and light-controlling element | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2000009115-A1 | GRP RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009116-A1 | GRP RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999062520-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5939545-A | MODULATING THE GABA.SUB.A (GAMMA-AMINOBUTYRIC ACID A) RECEPTOR-CHLORIDE IONOPHORE COMPLEX TO ALLEVIATE STRESS, ANXIETY, SEIZURES, MOOD DISORDERS, PMS (PREMENSTRUAL SYNDROME) AND PND (POSTNATAL DEPRESSION) AND TO INDUCE ANESTHESIA | COCENSYS, INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998045265-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-15 | — | — | WO | disclosed |
| EP-0752860-A4 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0752860-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995021617-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | ALDH1A1 531/4885MTOR 262/4885MEN1 1979/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | ALDH1A1 3030/4885MTOR 171/4885MEN1 2739/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | ALDH1A1 3260/4885MTOR 1373/4885MEN1 214/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | ALDH1A1 3260/4885MTOR 1373/4885MEN1 214/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | ALDH1A1 3824/4885MTOR 488/4885MEN1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.